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Although breast cancer screening has been shown to work in randomised trials, there is a need to evaluate service screening
programmes to ensure that they are delivering the benefit indicated by the trials. We carried out a case–control study to investigate
the effect of mammography service screening, in the NHS breast screening programme, on breast cancer mortality in the East Anglian
region of the UK. Cases were deaths from breast cancer in women diagnosed between the ages of 50 and 70 years, following the
instigation of the East Anglia Breast Screening Programme in 1989. The controls were women (two per case) who had not died of
breast cancer, from the same area, matched by date of birth to the cases. Each control was known to be alive at the time of death of
her matched case. All women were known to the breast screening programme and were invited, at least once, to be screened. There
were 284 cases and 568 controls. The odds ratio (OR) for risk of death from breast cancer in women who attended at least one
routine screen compared to those who did not attend was 0.35 (CI: 0.24, 0.50). Adjusting for self-selection bias gave an estimate of
the breast cancer mortality reduction associated with invitation to screening of 35% (OR¼0.65, 95% CI: 0.48, 0.88). The effect of
actually being screened was a 48% breast cancer mortality reduction (OR¼0.52, 95% CI: 0.32, 0.84). The results suggest that the
National Breast Screening Programme in East Anglia is achieving a reduction in breast cancer deaths, which is at least consistent with
the results from the randomised controlled trials of mammographic screening.
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Randomised trials have shown that breast screening reduces breast
cancer mortality (Jonsson et al, 2000, 2001, 2003; Duffy et al, 2002;
Nystro ¨m et al, 2002; Tabar et al, 2003). Whether this is achieved in
routine practice requires monitoring as certain factors might alter
the effect. These include technical changes in the mammographic
equipment since the trials, different screening frequencies to those
of the trials, expertise of the professionals involved, and quality
of the assessment process. For this reason, quality assurance is a
fundamental part of the National Health Service Breast Screening
Programme (NHSBSP), which aims at minimum standards and
improved performance so that women have access to high-quality
screening service wherever they live (NHS, 2006).
The case–control design is convenient and its basic principle
here is simple: women who have died from the disease are selected
as the cases and for each, we select as controls a number of age-
matched women (usually one or two) known to be alive at the time
of death of the case. We then compare the screening histories of
cases and controls prior to the diagnosis dates of the cases. If the
screening is reducing mortality from the disease, the cases will
tend to have lesser screening histories than the controls.
The design is prone to certain biases, in particular, self-selection
bias, since women who accept the invitation to screening may have
better health status a priori than those who do not, conferring a
reduced likelihood of dying from the disease independent of
screening. This is a bias in favour of screening, and a method for
correcting it is given by Duffy et al (2002).
We therefore conducted a case–control study to
(i) estimate the effect of the NHSBSP on breast cancer mortality
in the East Anglian region of the UK, adjusting for self-
selection bias; and
(ii) ascertain whether the reduction in breast cancer mortality
being achieved is consistent with that observed in the
randomised screening trials.
MATERIALS AND METHODS
All female residents of the East Anglian region (as delineated when
screening began) aged 50–70 years and registered with a general
practitioner were invited to attend breast screening once in every 3
years. The NHSBSP was established in the counties of Norfolk,
Suffolk, and Cambridgeshire in 1989.
For sample size, assuming a relative risk of 0.68 (Cuzick et al,
1997), and a 70% coverage, 264 cases and 528 matched controls
would detect a significant effect with 80% power at the 5% level
with a two-sided test (Breslow and Day, 1987). We therefore aimed
for 300 cases and 600 controls as a fail-safe measure. Cases were
deaths from female breast cancer in women aged 50–70 years at
Received 24 August 2007; revised 2 November 2007; accepted 5
November 2007; published online 4 December 2007
*Correspondence: Dr PC Allgood; E-mail: prue.allgood@cancer.org.uk
British Journal of Cancer (2008) 98, 206–209
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
ydiagnosis from 1995 onwards, to avoid the accumulation found in
the prevalent round of the screening programme, and to minimise
screening opportunity bias (Walter, 2003). Deaths were included
for which breast cancer was given as the primary or a contributory
cause on the death certificate.
We excluded those women who had not been invited to breast
screening at least once. Cases were taken at random from the EA
cancer registry database. There were two controls for each case and
matched by date of birth, most coming from the same health
authority. The controls were all alive at the time of death of their
case and were also known to the data source before the diagnosis
of the case. Controls were obtained from the National Health
Service (NHS) Exeter System database and individual screening
units. Each control was allocated a pseudodiagnosis date equal to
the date of diagnosis of that control’s matched case. The following
information was obtained:
  date of birth,
  date of diagnosis (if a case),
  stage at diagnosis (if a case),
  date of death (if a case), and
  complete screening history including dates of invitations and
attendances, and outcomes of attendances.
Statistical analysis
The data were analysed by conditional logistic regression. The
primary outcome of whether a woman had ever attended breast
screening prior to diagnosis/pseudodiagnosis is potentially subject
to self-selection or healthy volunteer bias, as it compares women
who choose to take up the invitation to screening with women who
do not. The latter may have poorer health a priori and therefore be
more likely to die of the disease, independent of screening. An
adjustment can be made for this using the relative rate of breast
cancer deaths in non-attenders in the randomised trials compared
to the trial controls (Duffy et al, 2002).
As an alternative, we adjusted for socio-economic status as
measured by the index of multiple deprivation (IMD) derived from
the womens’ postcodes, in the logistic regression, as this is the
main confounding factor of outcome and attendance. The IMD is
an area-based measure of relative deprivation, based on census
statistics for overcrowded housing and other factors. Secondary
analyses included the time since last screen attended, age at first
attendance, and the number of screens attended.
RESULTS
Out of the 300 cases identified, 16 were excluded because they were
diagnosed while awaiting their first screening invitation. The
remaining 284 were matched on birth date to two controls each,
giving a total study population of 852 women.
Slightly more controls than cases were in the two most affluent
deprivation groups 1 and 2 (51 versus 48%) and slightly fewer in
groups 3 and 4, but this was not significant (P¼0.3). The average
age at diagnosis/pseudodiagnosis was 60.7 years (range 50.4–70.5)
for both cases and controls as expected due to the matching. Mean
age at first screen was 55.3 for cases and 55.5 for controls (Table 1).
The mean number of screens was 1.39 for the cases compared with
1.70 for the controls, a significant difference (Po0.001).
More than 85% (242/284) of the cases presented symptomati-
cally, 58% as interval cancers and 27% in women who had never
attended screening. As might be expected with fatal cancers, the
tumours were at relatively advanced stages, with 49% being at
TMN stage 2 and 37% at stage 3 or 4. The average age at death
was 63.0 years (range 50.8–77.6) and average time from diagnosis
to death was 2.4 years, ranging from 3 days to 8.8 years. The years
of diagnosis and death ranged from 1995 to 2004.
The unadjusted OR of women who attended at least one routine
screen compared to those who never attended screening was
0.35 (95% CI: 0.24, 0.51; Po0.001) (Table 2). Adjusting for self-
selection bias using the more conservative intention-to-treat
analysis (Duffy et al, 2002) gave a 35% estimated mortality
reduction (OR¼0.65, 95% CI: 0.48, 0.88; P¼0.005). Actually being
screened, adjusted for self-selection bias, was associated with
a 48% reduction (OR¼0.52, 95% CI 0.32, 0.84; P¼0.007). As
an alternative to self-selection bias correction, adjustment for
IMD had no effect on the OR associated with ever being screened
(OR¼0.35, 95% CI 0.23–0.51, Po0.001).
The major effect of any screens attended is an approximately
60% lower risk of death from breast cancer compared to those who
had attended none; there was no significant effect for number of
screens attended. Risk was higher in those with a screen within
1 year than those whose last screen was between 1 and 2 years
prior to diagnosis or pseudodiagnosis, due to deaths from screen-
detected cancers. Thereafter, risk increased with increasing time
since last screen. Risk was higher in those whose first screen took
Table 1 Patient characteristics, screening history by case–control status
Cases Controls
Total numbers 284 568
Index of multiple deprivation (IMD), N (%)
a
1st quartile 75 (26) 135 (25)
2nd quartile 61 (22) 146 (26)
3rd quartile 68 (24) 139 (25)
4th quartile 80 (28) 132 (24)
Mean age at diagnosis or pseudodiagnosis
(range)
60.7 (50.4–70.5)60.7 (50.4–70.5)
Age group, N (%)
50–54 50 (18) 100 (18)
55–59 85 (29) 170 (29)
60–64 67 (24) 134 (24)
65+ 82 (29) 164 (29)
Mean age at first screen, years (range) 55.3 (45.2–65.4)55.5 (43.5–65.5)
Number of screening visits, N (%)
0 77 (27) 63 (11)
1 87 (31) 185 (32)
2 66 (23) 198 (35)
3 45 (16) 106 (19)
4+ 10 (3) 16 (3)
Mean number of screens (range) 1.39 (0–5) 1.70 (0–5)
Outcome of first screen, N (%)
Routine recall 190 (92) 498 (99)
Recall to assessment and benign 4 (2) 7 (1)
Recall to assessment and cancer 13 (6) 0 (0)
Mode of detection, N (%)
Non-attender 77 (27)
First screen (screen detected) 10 (3)
Subsequent screen (screen detected) 32 (12)
Interval cancer 165 (58)
TMN stage, N (%)
b
1 37 (14)
2 137 (49)
3 25 (9)
4 76 (28)
Mean age at death, years (range) 63.0 (50.8–77.6)
a16 (2.8%) controls had missing IMD.
b9 (3.2%) cases had missing TMN stage.
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was not significant, possibly due to the small numbers.
DISCUSSION
The results of this study are encouraging. After adjusting for self-
selection bias, we found a significant 35% reduction in breast
cancer mortality in association with invitation to screening and a
significant 48% reduction with actually being screened, if anything,
exceeding the benefits in the randomised trials (Smith et al, 2004).
However, the correction method makes an important assumption
that the relative mortality for non-compliers compared with a
population not invited for screening is the same in the programme
in question as in the randomised trials. From the available
information (the Swedish Two-county, Malmo ¨, Gothenburg,
Stockholm and Canadian trials) (Duffy et al, 2002), non-attenders
had a 36% higher risk of breast cancer mortality than uninvited
controls. This may not hold for our population, but it seems likely
that there is at least some self-selection bias, and the uncorrected
estimates of the mortality reduction seem implausible.
There is a suggestive increase in risk with first screen at 52 or
over, suggesting that there is an advantage to a first screen at the
lower age limit of 50, though the trend was not significant; it
should be examined in other studies.
Adjustment for IMD made no difference to the estimated effect
of screening on risk, perhaps because although socioeconomic
status is strongly associated with screening in urban areas, it may
not be so in rural areas. In East Anglia, IMD was not strongly
related to screening exposure, around 84% regardless of IMD.
There was no substantial trend in risk with number of screens
attended, consistent with the fact that only the screen at which a
cancer is detected actually confers a benefit (Elmore et al, 2005).
Aside from a high risk in those very recently screened, there was
an increase in the risk with time since last screen. The high risk in
those screened in the last year could be due to screen-detected
cancers. When these are excluded, the ORs for 1–2, 2–4, and 4 or
more years since last screen, relative to less than 1 year, were 1.05,
1.32, and 1.49 respectively.
From other case–control screening studies, there is a range of
results from a very small benefit to large reductions in mortality as
observed in this study (Palli et al, 1989; Mittenburg et al, 1998;
Fielder et al, 2004; Elmore et al, 2005; Gabe et al, 2007). Our
estimated benefit may be slightly biased in favour of screening by
the selection of recently diagnosed cases (1995–2004), which will
of necessity be relatively rapidly fatal and therefore may under-
represent screening-exposed fatal cancers. Restricting analysis to
those diagnosed before 1999, we obtain an uncorrected mortality
reduction of 59% with ever being screened, and self-selection bias
corrected estimates of 27% for invitation to screening, and 37% for
actually being screened.
In conclusion, this study shows strong evidence that the NHS
breast screening programme in East Anglia is achieving at least a
30% reduction in breast cancer mortality in women attending
screening, consistent with the randomised trials. We recommend
expanding the case–control study to other regions of the UK and
internationally.
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